Loading
A phase 1/2 trial of ALE.P03 in non-small-cell lung cancer, colorectal cancer, biliary tract cancer and bladder & urothelial cancer, run by Alentis Therapeutics AG, now recruiting.
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors is a phase 1/2 interventional study registered as NCT07169734 by Alentis Therapeutics AG, with 180 participants planned, started 2025-08-26 and due to reach its primary completion in 2029-04-05. Interventions recorded: ALE.P03.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Alentis Therapeutics, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/